FY2026 Earnings Estimate for Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Issued By Zacks Research

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Investment analysts at Zacks Research reduced their FY2026 EPS estimates for shares of Sarepta Therapeutics in a research report issued to clients and investors on Tuesday, April 23rd. Zacks Research analyst S. Ganoria now forecasts that the biotechnology company will earn $10.13 per share for the year, down from their prior forecast of $11.48. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $2.13 per share.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Wednesday, February 28th. The biotechnology company reported $0.47 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.50. Sarepta Therapeutics had a negative net margin of 43.11% and a negative return on equity of 18.97%. The business had revenue of $396.80 million for the quarter, compared to analysts’ expectations of $387.18 million. During the same period in the prior year, the company posted ($1.24) EPS. The business’s revenue for the quarter was up 53.6% on a year-over-year basis.

Other equities research analysts have also recently issued reports about the stock. Citigroup increased their price objective on shares of Sarepta Therapeutics from $160.00 to $172.00 and gave the company a “buy” rating in a research note on Thursday, February 29th. UBS Group increased their price objective on shares of Sarepta Therapeutics from $164.00 to $167.00 and gave the company a “buy” rating in a research note on Friday, March 1st. Mizuho increased their price objective on shares of Sarepta Therapeutics from $130.00 to $145.00 and gave the company a “buy” rating in a research note on Wednesday, February 14th. Barclays increased their price objective on shares of Sarepta Therapeutics from $141.00 to $185.00 and gave the company an “overweight” rating in a research note on Thursday, February 29th. Finally, Evercore ISI upped their target price on shares of Sarepta Therapeutics from $108.00 to $138.00 and gave the company an “in-line” rating in a report on Tuesday, February 20th. Four investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $156.60.

Sarepta Therapeutics Price Performance

Shares of NASDAQ SRPT opened at $128.77 on Thursday. The stock has a market cap of $12.09 billion, a price-to-earnings ratio of -21.04 and a beta of 0.94. Sarepta Therapeutics has a 52 week low of $55.25 and a 52 week high of $159.89. The company’s 50-day moving average price is $126.11 and its 200 day moving average price is $110.47. The company has a current ratio of 3.95, a quick ratio of 3.45 and a debt-to-equity ratio of 1.32.

Institutional Trading of Sarepta Therapeutics

Several large investors have recently bought and sold shares of the company. GAMMA Investing LLC grew its position in Sarepta Therapeutics by 37.0% in the first quarter. GAMMA Investing LLC now owns 322 shares of the biotechnology company’s stock valued at $42,000 after acquiring an additional 87 shares in the last quarter. Vanguard Capital Wealth Advisors grew its position in shares of Sarepta Therapeutics by 3.8% during the fourth quarter. Vanguard Capital Wealth Advisors now owns 2,450 shares of the biotechnology company’s stock worth $236,000 after buying an additional 90 shares in the last quarter. DMC Group LLC grew its position in shares of Sarepta Therapeutics by 2.9% during the third quarter. DMC Group LLC now owns 3,297 shares of the biotechnology company’s stock worth $400,000 after buying an additional 93 shares in the last quarter. WCM Investment Management LLC grew its position in shares of Sarepta Therapeutics by 2.3% during the first quarter. WCM Investment Management LLC now owns 6,279 shares of the biotechnology company’s stock worth $813,000 after buying an additional 142 shares in the last quarter. Finally, Cary Street Partners Investment Advisory LLC grew its position in shares of Sarepta Therapeutics by 154.0% during the third quarter. Cary Street Partners Investment Advisory LLC now owns 254 shares of the biotechnology company’s stock worth $31,000 after buying an additional 154 shares in the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

Insider Activity at Sarepta Therapeutics

In related news, Director Kathryn Jean Boor sold 761 shares of the firm’s stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $122.93, for a total value of $93,549.73. Following the transaction, the director now owns 7,516 shares in the company, valued at $923,941.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other Sarepta Therapeutics news, Director Stephen Mayo sold 3,135 shares of the stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $122.96, for a total value of $385,479.60. Following the completion of the sale, the director now owns 6,621 shares of the company’s stock, valued at $814,118.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Kathryn Jean Boor sold 761 shares of the stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $122.93, for a total transaction of $93,549.73. Following the completion of the sale, the director now directly owns 7,516 shares of the company’s stock, valued at approximately $923,941.88. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 22,096 shares of company stock worth $2,739,419. Company insiders own 7.40% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.